The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is considered to be a highly immunosuppressive and heterogenous neoplasm. Despite improved knowledge regarding the genetic background of the tumor and better understanding of the tumor microenvironment, immune checkpoint inhibitor therapy (targeting CTLA4, PD1, PDL1) has not been very successful against PDAC. The robust desmoplastic stroma, along with an extensive extracellular matrix (ECM) that is rich in hyaluronan, plays an integral role in this immune evasion. Hexosamine biosynthesis pathway (HBP), a shunt pathway of glycolysis, is a metabolic node in cancer cells that can promote survival pathways on the one hand and influence the hyaluronan synthesis in the ECM on the other. The rate-limiting enzyme of the pathway, glutamine-fructose amidotransferase 1 (GFAT1), uses glutamine and fructose 6-phosphate to eventually synthesize uridine diphosphate N-acetylglucosamine (UDP-GlcNAc). In the current manuscript, we targeted this glutamine-utilizing enzyme by a small molecule glutamine analog (6-diazo-5-oxo-l-norleucine [DON]). Our results showed that DON decreased the self-renewal potential and metastatic ability of tumor cells. Further, treatment with DON decreased hyaluronan and collagen in the tumor microenvironment, leading to an extensive remodeling of the ECM and an increased infiltration of CD8+ T cells. Additionally, treatment with DON sensitized pancreatic tumors to anti-PD1 therapy, resulting in tumor regression and prolonged survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“recent advances have optimized DON as a pro-drug with pharmacokinetic properties that increase tumor targeting203, including an orally available analog with promising pre-clinical results in murine PDAC models204”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [204]
In the citing paper
“recent studies have shown that the use of DON or analogs in murine PDAC models also appear to have immunomodulatory effects204,205”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [204]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“the tumor improves response to anti-PD1 therapy (65).”
BackgroundOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G. M., Budinger, G. R. S., & Chandel, N. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003428107 · Cited by 1,742
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Ghamry-Barrin, S., Kantari‐Mimoun, C., Bercovici, N., Guérin, M. V., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 941
Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture
Apte, M. V., Haber, P., Applegate, T. L., Norton, I. D., McCaughan, G. W., Korsten, M. A., Pirola, R. C., & Wilson, J. S. (1998) · Gut · doi:10.1136/gut.43.1.128 · Cited by 920
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki–Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 857
Glutamine Metabolism in Cancer: Understanding the Heterogeneity
Cluntun, A. A., Lukey, M. J., Cerione, R. A., & Locasale, J. W. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.01.005 · Cited by 796
Stromal biology and therapy in pancreatic cancer
Neeße, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2010) · Gut · doi:10.1136/gut.2010.226092 · Cited by 780
Interstitial leukocyte migration and immune function
Friedl, P., & Weigelin, B. (2008) · Nature Immunology · doi:10.1038/ni.f.212 · Cited by 606
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S., Loo, A. T., Miller, C., deBeaumont, R. S., Stegmeier, F., Yao, Y.-M. M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0802655105 · Cited by 565
Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2003) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532
Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growth
Gaglio, D., Metallo, C. M., Gameiro, P. A., Hiller, K., Danna, L. S., Balestrieri, C., Alberghina, L., Stephanopoulos, G., & Chiaradonna, F. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.56 · Cited by 492
Single-vector inducible lentiviral RNAi system for oncology target validation
Wiederschain, D., Susan, W. N., Chen, L., Loo, A. T., Yang, G., Huang, A., Chen, Y., Caponigro, G., Yao, Y.-M., Christoph Lengauer, C., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7701 · Cited by 441
Zachara, N. E., & Hart, G. W. (2004) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2004.03.016 · Cited by 438
Tumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy
Bertero, T., Oldham, W. M., Grasset, E. M., Bourget, I., Boulter, E., Pisano, S., Hofman, P., Bellvert, F., Meneguzzi, G., Bulavin, D. V., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.012 · Cited by 393
Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & di Magliano, M. P. (2016) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 339
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
Stromnes, I. M., Brockenbrough, J. S., Izeradjene, K., Carlson, M. A., Cuevas, C. M., Simmons, R. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Gut · doi:10.1136/gutjnl-2013-306271 · Cited by 336
Franciszkiewicz, K., Boissonnas, A., Boutet, M., Combadière, C., & Mami‐Chouaib, F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2027 · Cited by 292
Systemic and local immunosuppression in pancreatic cancer patients.
von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Jöhnk, C., Henne‐Bruns, D., Kremer, B., & Kalthoff, H. (2001) · PubMed · Cited by 279
Glutamine Metabolism in Cancer
Li, T., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 242
Ao, Z., Shah, S. H., Machlin, L., Parajuli, R., Miller, P. C., Rawal, S., Williams, A. J., Côté, R. J., Lippman, M. E., Datar, R. H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1633 · Cited by 238
We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine
Lemberg, K. M., Vornov, J. J., Rais, R., & Slusher, B. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1148 · Cited by 234
Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
Hartmann, N., Giese, N. A., Giese, T., Poschke, I. C., Offringa, R., Werner, J. M., & Ryschich, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2972 · Cited by 231
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
Chiorean, E. G., & Coveler, A. L. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s60328 · Cited by 217
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Martínez‐Bosch, N., Vinaixa, J., & Navarro, P. (2018) · Cancers · doi:10.3390/cancers10010006 · Cited by 216
Metabolic control of hyaluronan synthases
Vigetti, D., Viola, M., Karousou, E. G., Luca, G. D., & Passi, A. G. (2013) · Matrix Biology · doi:10.1016/j.matbio.2013.10.002 · Cited by 191
Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 181
Nagathihalli, N. S., Castellanos, J. A., Shi, C.-J., Beesetty, Y., Reyzer, M. L., Caprioli, R., Chen, X., Walsh, A., Skala, M., Moses, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.058 · Cited by 178
Ge, J., Cui, H., Xie, N., Banerjee, S., Guo, S., Dubey, S., Barnes, S., & Liu, G. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0238oc · Cited by 166
Self-citationHu, H., Hang, J.-J., Han, T., Zhuo, M., Jiao, F., & Wang, L.-W. (2016) · Tumor Biology · doi:10.1007/s13277-015-4741-z · Cited by 162
Elahi-Gedwillo, K. Y., Carlson, M., Zettervall, J., & Provenzano, P. P. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1334 · Cited by 158
Doherty, G. J., Tempero, M. A., & Corrie, P. G. (2017) · Future Oncology · doi:10.2217/fon-2017-0338 · Cited by 157
Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis
Yuzhalin, A. E., Lim, S. Y., Kutikhin, A. G., & Gordon-Weeks, A. N. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.09.002 · Cited by 147
Jiang, M., Xu, B., Li, X., Shang, Y., Chu, Y., Wang, W., Chen, D., Wu, N., Hu, S., Zhang, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0435-5 · Cited by 145
Rais, R., Jančařík, A., Tenora, L., Nedelcovych, M., Alt, J., Englert, J., Rojas, C., Le, A., Elgogary, A., Tan, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01069 · Cited by 138
Hyaluronan, Cancer-Associated Fibroblasts and the Tumor Microenvironment in Malignant Progression
McCarthy, J. B., El‐Ashry, D., & Turley, E. A. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00048 · Cited by 130
Cervantes-Madrid, D., Romero, Y., & Dueñas‐González, A. (2015) · BioMed Research International · doi:10.1155/2015/690492 · Cited by 125
The complex landscape of pancreatic cancer metabolism
Sousa, C. M., & Kimmelman, A. C. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu097 · Cited by 125
Zhang, W., Bouchard, G., Yu, A., Shafiq, M., Jamali, M., Shrager, J. B., Ayers, K., Bakr, S. H., Gentles, A. J., Diehn, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2928 · Cited by 124
Nakajima, C., Uekusa, Y., 岩崎, 正., Yamaguchi, N., Mukai, T., Gao, P. H., Tomura, M., Ono, S., Tsujimura, T., Fujiwara, H., et al. (2001) · PubMed · Cited by 119
Dauer, P., Zhao, X., Gupta, V. K., Sharma, N., Kesh, K., Gnamlin, P., Dudeja, V., Vickers, S. M., Banerjee, S., & Saluja, A. K. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2320 · Cited by 115
Self-citationO-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway
Ferrer, C. M., Lu, T. Y., Bacigalupa, Z. A., Katsetos, C. D., Sinclair, D. A., & Reginato, M. J. (2016) · Oncogene · doi:10.1038/onc.2016.228 · Cited by 111
Banerjee, S., Sangwan, V., McGinn, O., Chugh, R., Dudeja, V., Vickers, S. M., & Saluja, A. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.500983 · Cited by 110
Self-citationBanerjee, S., Modi, S., McGinn, O., Zhao, X., Dudeja, V., Ramakrishnan, S., & Saluja, A. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1155 · Cited by 108
Self-citationImpact of tumour associated macrophages in pancreatic cancer
Mielgo, A., & Schmid, M. C. (2013) · BMB Reports · doi:10.5483/bmbrep.2013.46.3.036 · Cited by 103
CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice
Zhang, Y., Yan, W., Mathew, E., Bednar, F., Wan, S., Collins, M. A., Evans, R. A., Welling, T. H., Vonderheide, R. H., & di Magliano, M. P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0016-t · Cited by 102
O-GlcNAc modification: a nutritional sensor that modulates proteasome function
Zachara, N. E., & Hart, G. W. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.03.005 · Cited by 99
A Trickster in Disguise: Hyaluronan’s Ambivalent Roles in the Matrix
Bohaumilitzky, L., Huber, A., Stork, E. M., Wengert, S., Woelfl, F., & Boehm, H. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00242 · Cited by 94
Friedl, P., Bröcker, E. ‐., & Zänker, K. S. (1998) · Cell Communication & Adhesion · doi:10.3109/15419069809004478 · Cited by 81
Chanmee, T., Ontong, P., Izumikawa, T., Higashide, M., Mochizuki, N., Chokchaitaweesuk, C., Khansai, M., Nakajima, K., Kakizaki, I., Kongtawelert, P., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.751263 · Cited by 79
Sharon, Y., Alon, L. T., Glanz, S., Servais, C., & Erez, N. (2013) · Journal of Visualized Experiments · doi:10.3791/4425 · Cited by 77
CD133+ Tumor Initiating Cells in a Syngenic Murine Model of Pancreatic Cancer Respond to Minnelide
Banerjee, S., Nomura, A., Sangwan, V., Chugh, R., Dudeja, V., Vickers, S. M., & Saluja, A. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2947 · Cited by 77
Self-citationO-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability
Sharma, N., Gupta, V. K., Dauer, P., Kesh, K., Hadad, R., Giri, B., Chandra, A., Dudeja, V., Slawson, C. M., Banerjee, S., et al. (2019) · Theranostics · doi:10.7150/thno.32615 · Cited by 71
Self-citationCytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia.
Lyons, S. D., Sant, M. E., & Christopherson, R. I. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38603-x · Cited by 70
High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer
Yang, C., Peng, P., Li, L., Shao, M., Zhao, J., Wang, L., Duan, F., Song, S., Wu, H., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep39044 · Cited by 67
Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Asthana, A., Ramakrishnan, P., Vicioso, Y. M., Zhang, K., & Parameswaran, R. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0426 · Cited by 59
Ali, A. A., Kim, S. H., Kim, M. J., Choi, M. Y., Kang, S. S., Cho, G. J., Kim, Y. S., Choi, J., & Choi, W. S. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.2309 · Cited by 56
High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma
Li, L., Shao, M., Peng, P., Yang, C., Song, S., Duan, F., Jia, D., Zhang, M., Zhao, J., Zhao, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15164 · Cited by 48
Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
Sklaroff, R. B., Casper, E. S., Magill, G. B., & Cw, Y. (1980) · PubMed · Cited by 29
Chronic pancreatitis changes in high-risk individuals for pancreatic ductal adenocarcinoma
Thiruvengadam, S. S., Chuang, J., Huang, R. J., Girotra, M., & Park, W. G. (2018) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2018.08.029 · Cited by 26
Sangwan, V., Banerjee, S., Jensen, K. M., Chen, Z., Chugh, R., Dudeja, V., Vickers, S. M., & Saluja, A. K. (2015) · Pancreas · doi:10.1097/mpa.0000000000000317 · Cited by 23
Self-citationOvercoming immune evasion in pancreatic cancer: the combination matters
Michl, P., & Krug, S. (2017) · Gut · doi:10.1136/gutjnl-2017-315443 · Cited by 19
ER stress and hexosamine pathway during tumourigenesis: A pas de deux?
Vasseur, S., & Manié, S. N. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.04.001 · Cited by 18
Sweet connections: O-GlcNAcylation links cancer cell metabolism and survival
Ferrer, C. M., & Reginato, M. J. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.961809 · Cited by 16
Szeliga, M., Ćwikła, J. B., Obara‐Michlewska, M., Cichocki, A. S., & Albrecht, J. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.11.017 · Cited by 6
Flagged first, then by citations
Cited by
Sorted by citations
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,328
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
Metabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877
Targeting glutamine metabolism as a therapeutic strategy for cancer
Jin, J., Byun, J., Choi, Y., & Park, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00971-9 · Cited by 605
Metadata
- Authors
- Sharma, N. S., Gupta, V. K., Garrido, V. T., Hadad, R., Durden, B. C., Kesh, K., Giri, B., Ferrantella, A., Dudeja, V., Saluja, A., & Banerjee, S.
- Affiliations
- University of Miami (US)
- Corresponding author
- Banerjee, Sulagna
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2019-12-03
- Volume
- 130
- Issue
- 1
- Pages
- 451-465
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6934212
- OpenAlex
- W2980538229
- Cited by
- 203
- References
- 73
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 22 · 2023: 50 · 2022: 39 · 2021: 37 · 2020: 14 · 2019: 1
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01-CA170946,to AS, R01-CA124723,to AS, R01- CA184274,to SB)
- Katherine and Robert Goodale foundation support (NA)
- Minneamrita Therapeutics LLC (NA)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Keywords
- pancreatic ductal adenocarcinoma, hexosamine biosynthetic pathway, 6-diazo-5-oxo-L-norleucine, anti-PD-1 therapy, immune checkpoint inhibitor resistance, hyaluronic acid, extracellular matrix remodeling, tumor microenvironment, CD8+ T cell infiltration, tumor self-renewal, metastasis, glutamine metabolism
- MeSH terms
- Animals, Diazooxonorleucine, Female, Hexosamines, Humans, Mice, Nude, Neoplasm Metastasis, Neoplasm Proteins, Pancreatic Neoplasms, CD8-Positive T-Lymphocytes, Carcinoma, Pancreatic Ductal, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
